Retatrutide
Lyophilized research reference material. Released with a per-lot Certificate of Analysis. For laboratory research use only.
- All products currently listed on this site are for research purposes ONLY.
- All products sold on this website are intended for research and identification purposes only.
- These products are not intended for human dosing, injections, or ingestion.
- Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption.
Research background
Retatrutide (development code LY3437943) is an investigational single-molecule triple agonist of the GIP, GLP-1, and glucagon receptors. Engaging all three incretin/glucagon pathways is studied for its combined effects on energy metabolism in research models, distinguishing it from selective GLP-1 and dual GIP/GLP-1 agonists.
Phase 2 trials characterized its metabolic activity across the range studied. As an investigational compound, retatrutide has not completed phase 3 development and is not approved for any use.
Summary of published scientific literature provided for laboratory research reference only. It is not a claim of safety, efficacy, or suitability for any use, and does not describe or recommend any human or veterinary use.
Selected references
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526.
- Rosenstock J, et al. Retatrutide in patients with type 2 diabetes: a phase 2 trial. The Lancet. 2023;402(10401):529-544.
- Coskun T, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist. Cell Metabolism. 2022;34(9):1234-1247.
Trademarks & attribution
Retatrutide (LY3437943) is an investigational compound under development by Eli Lilly and Company with no approved or trademarked drug product. Catalyst Research Labs is not affiliated with Eli Lilly. Supplied as reference material only.
